Combination locoregional and systemic therapies in hepatocellular carcinoma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39993404.
- Also identified by DOI 10.1016/S2468-1253(24)00247-4.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Locoregional therapies play a fundamental role in the treatment of patients with early and intermediate and locally advanced hepatocellular carcinomas. With encouraging recent advances in immunotherapy-based systemic therapies, locoregional therapies are being both promoted and challenged by new systemic therapy options. Combined locoregional and systemic therapies might enhance treatment outcomes compared with either option alone. This Series paper summarises the existing data on locoregional and systemic therapies for hepatocellular carcinoma, and discusses evidence from studies investigating their combination with a focus on their synergistic efficacy and safety.
Medical subject headings
- Carcinoma, Hepatocellular
- Liver Neoplasms